First Trust Advisors LP Buys 62,718 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

First Trust Advisors LP boosted its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 2.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,240,932 shares of the company's stock after buying an additional 62,718 shares during the period. First Trust Advisors LP owned 0.10% of Takeda Pharmaceutical worth $42,910,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Versant Capital Management Inc acquired a new stake in shares of Takeda Pharmaceutical in the 4th quarter worth approximately $26,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Takeda Pharmaceutical in the 3rd quarter worth $40,000. Farther Finance Advisors LLC raised its position in Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after acquiring an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. acquired a new position in Takeda Pharmaceutical in the fourth quarter worth approximately $52,000. Finally, Cromwell Holdings LLC acquired a new stake in shares of Takeda Pharmaceutical during the fourth quarter worth $61,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Up 0.5 %

Shares of NYSE TAK traded up $0.08 during mid-day trading on Tuesday, reaching $15.24. The company had a trading volume of 242,756 shares, compared to its average volume of 1,860,539. The stock has a fifty day moving average of $14.75 and a two-hundred day moving average of $13.94. Takeda Pharmaceutical Company Limited has a 12-month low of $12.58 and a 12-month high of $15.37. The company has a market capitalization of $48.48 billion, a price-to-earnings ratio of 38.09, a PEG ratio of 0.24 and a beta of 0.39. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, equities research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.